Compare OXM & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | PRTA |
|---|---|---|
| Founded | 1942 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.0M | 458.4M |
| IPO Year | 1994 | 2013 |
| Metric | OXM | PRTA |
|---|---|---|
| Price | $26.34 | $8.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $38.00 | $19.00 |
| AVG Volume (30 Days) | ★ 481.0K | 325.2K |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.25 | 0.26 |
| Revenue | ★ $1,477,834,000.00 | $814,000.00 |
| Revenue This Year | $2.85 | $1,111.38 |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | ★ $6.61 | $34.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.85 | $7.73 |
| 52 Week High | $49.58 | $11.80 |
| Indicator | OXM | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 24.33 | 49.87 |
| Support Level | N/A | $8.12 |
| Resistance Level | $42.57 | $9.36 |
| Average True Range (ATR) | 1.41 | 0.31 |
| MACD | -0.39 | -0.04 |
| Stochastic Oscillator | 0.00 | 44.31 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.